TY - JOUR
T1 - Kynureninase deficiency ameliorated monocytic recruitment and severity in a mouse model of multiple sclerosis
AU - Yoshidomi, Koyo
AU - Kunisawa, Kazuo
AU - Hasegawa, Masaya
AU - Kon, Yuki
AU - Kosuge, Aika
AU - Tanabe, Moeka
AU - Ojika, Haruto
AU - Yamamoto, Yasuko
AU - Fujigaki, Hidetsugu
AU - Fujigaki, Suwako
AU - Tezuka, Hiroyuki
AU - Saitoh, Sei
AU - Kumamoto, Kanako
AU - Kugita, Masanori
AU - Nagao, Shizuko
AU - Saito, Kuniaki
AU - Nabeshima, Toshitaka
AU - Mouri, Akihiro
N1 - Publisher Copyright:
© 2026 Elsevier Ltd.
PY - 2026/5
Y1 - 2026/5
N2 - Multiple sclerosis (MS) is a common autoimmune demyelinating disease of the central nervous system (CNS). Although activation of the kynurenine (KYN) pathway has been observed in patients with MS, its pathological significance remains unclear. In this study, we investigated the role of the KYN pathway in MS using an experimental autoimmune encephalomyelitis (EAE) mouse model, a widely recognized animal model of MS. We found an increase in the expression of kynureninase (KYNU), a key enzyme in the KYN pathway that is specifically localized within monocytes in the spinal cord of EAE mice. This was accompanied by a significant accumulation of quinolinic acid (QUIN) in the spinal cord. Importantly, similar increases in KYNU expression and QUIN levels were observed in the spinal cord of proteolipid protein overexpressing mice (PLP-tg mice), another model of demyelination. Notably, KYNU knockout (KO) reduced EAE severity and monocyte recruitment to the spinal cord of EAE model mice. These findings suggest that the increase in KYNU expression and the subsequent accumulation of QUIN may contribute to the exacerbation of MS. Taken together, our results indicate that KYNU could be a novel therapeutic target for MS.
AB - Multiple sclerosis (MS) is a common autoimmune demyelinating disease of the central nervous system (CNS). Although activation of the kynurenine (KYN) pathway has been observed in patients with MS, its pathological significance remains unclear. In this study, we investigated the role of the KYN pathway in MS using an experimental autoimmune encephalomyelitis (EAE) mouse model, a widely recognized animal model of MS. We found an increase in the expression of kynureninase (KYNU), a key enzyme in the KYN pathway that is specifically localized within monocytes in the spinal cord of EAE mice. This was accompanied by a significant accumulation of quinolinic acid (QUIN) in the spinal cord. Importantly, similar increases in KYNU expression and QUIN levels were observed in the spinal cord of proteolipid protein overexpressing mice (PLP-tg mice), another model of demyelination. Notably, KYNU knockout (KO) reduced EAE severity and monocyte recruitment to the spinal cord of EAE model mice. These findings suggest that the increase in KYNU expression and the subsequent accumulation of QUIN may contribute to the exacerbation of MS. Taken together, our results indicate that KYNU could be a novel therapeutic target for MS.
KW - Kynureninase
KW - Kynurenine pathway
KW - Monocytes
KW - Multiple sclerosis
KW - Quinolinic acid
UR - https://www.scopus.com/pages/publications/105032575476
UR - https://www.scopus.com/pages/publications/105032575476#tab=citedBy
U2 - 10.1016/j.neuint.2026.106141
DO - 10.1016/j.neuint.2026.106141
M3 - Article
C2 - 41794052
AN - SCOPUS:105032575476
SN - 0197-0186
VL - 195
JO - Neurochemistry International
JF - Neurochemistry International
M1 - 106141
ER -